Schizophrenia: Neural mechanisms for novel therapies

被引：49
作者：
Sawa, A
Snyder, SH
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
来源：
MOLECULAR MEDICINE | 2003年 / 9卷 / 1-2期
关键词：
D O I：
10.1007/BF03402101
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Although valuable antischizophrenic drugs exist, they only partially ameliorate symptoms and elicit substantial side effects. Classic neuroleptic drugs act by blocking dopamine receptors. They can relieve some symptoms but not behavioral withdrawal features that are designated "negative" symptoms. Clozapine and related newer atypical neuroleptics may be more efficacious in relieving negative symptoms. Understandng their actions may facilitate new drug discovery. Agents influencing glutamate neurotransmission and N-methyl-D-aspartate receptors, especially the cotransmitter D-serine, are promising. Stimulation of the alpha7 subtype of nicotinic acetylcholine receptor may also be efficacious. The search for genes linked to schizophrenic has revealed several leads that may permit development of novel therapeutic agents. Promising genes include disrupted-in-schizophrenia-1, dysbindin, and neuregulin.
引用
收藏
页码：3 / 9
页数：7
相关论文
共 44 条
[31]   INDICATORS OF LIABILITY TO SCHIZOPHRENIA - PERSPECTIVES FROM GENETIC EPIDEMIOLOGY [J].
MOLDIN, SO .
SCHIZOPHRENIA BULLETIN, 1994, 20 (01) :169-184
[32]   Schizophrenia and velo-cardio-facial syndrome [J].
Murphy, KC .
LANCET, 2002, 359 (9304) :426-430
[33]   High rates of schizophrenia in adults with velo-cardio-facial syndrome [J].
Murphy, KC ;
Jones, LA ;
Owen, MJ .
ARCHIVES OF GENERAL PSYCHIATRY, 1999, 56 (10) :940-945
[34]   Disrupted-in-schizophrenia-1 (DISC-1): Mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth [J].
Ozeki, Y ;
Tomoda, T ;
Kleiderlein, J ;
Kamiya, A ;
Bord, L ;
Fujii, K ;
Okawa, M ;
Yamada, N ;
Hatten, ME ;
Snyder, SH ;
Ross, CA ;
Sawa, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (01) :289-294
[35]   Mutant genes in familial Alzheimer's disease and transgenic models [J].
Price, DL ;
Sisodia, SS .
ANNUAL REVIEW OF NEUROSCIENCE, 1998, 21 :479-505
[36]   The mammalian brain high-affinity L-proline transporter is enriched preferentially in synaptic vesicles in a subpopulation of excitatory nerve terminals in rat forebrain [J].
Renick, SE ;
Kleven, DT ;
Chan, J ;
Stenius, K ;
Milner, TA ;
Pickel, VM ;
Fremeau, RT .
JOURNAL OF NEUROSCIENCE, 1999, 19 (01) :21-33
[37]   Schizophrenia: Diverse approaches to a complex disease [J].
Sawa, A ;
Snyder, SH .
SCIENCE, 2002, 296 (5568) :692-695
[38]   Preclinical Pharmacology of mGlu2/3 Receptor Agonists: Novel Agents for Schizophrenia? [J].
Schoepp, Darryle D. ;
Marek, Gerard J. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (02) :215-225
[39]   ANTIPSYCHOTIC DRUG DOSES AND NEUROLEPTIC-DOPAMINE RECEPTORS [J].
SEEMAN, P ;
LEE, T ;
CHAUWONG, M ;
WONG, K .
NATURE, 1976, 261 (5562) :717-719
[40]   Neuregulin 1 and susceptibility to schizophrenia [J].
Stefansson, H ;
Sigurdsson, E ;
Steinthorsdottir, V ;
Bjornsdottir, S ;
Sigmundsson, T ;
Ghosh, S ;
Brynjolfsson, J ;
Gunnarsdottir, S ;
Ivarsson, O ;
Chou, TT ;
Hjaltason, O ;
Birgisdottir, B ;
Jonsson, H ;
Gudnadottir, VG ;
Gudmundsdottir, E ;
Bjornsson, A ;
Ingvarsson, B ;
Ingason, A ;
Sigfusson, S ;
Hardardottir, H ;
Harvey, RP ;
Lai, D ;
Zhou, MD ;
Brunner, D ;
Mutel, V ;
Gonzalo, A ;
Lemke, G ;
Sainz, J ;
Johannesson, G ;
Andresson, T ;
Gudbjartsson, D ;
Manolescu, A ;
Frigge, ML ;
Gurney, ME ;
Kong, A ;
Gulcher, JR ;
Petursson, H ;
Stefansson, K .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) :877-892
12345